Motixafortide (BL-8040)

Motixafortide (formerly known as BL-8040/BKT140) is a novel selective inhibitor of the CXCR4 chemokine receptor. CXCR4, is a well validated therapeutic target that is involved in the mobilization and trafficking of hematopoetic stem cells, immune cells and cancer cells from the bone marrow and the lymph nodes to the peripheral blood. Motixafortide is currently being developed as a platform for several indications including mobilization of hematopoietic stem cells (HSCs) for autologous transplantations, treatment of solid tumors, and other hematological malignancies.

Motixafortide’s unique features including high-affinity, long receptor occupancy and inverse agonist activity position it as the best-in-class antagonist of CXCR4 in development.

Motixafortide (BL-8040)

Therapeutic areas

Therapeutic areas

Solid tumors
Stem cell mobilization
Hematological malignances

Mode of action

Mode of action

CXCR4 antagonism

Stage of development

Stage of development

Active clinical development with multiple Phase 2 and Phase 3 studies

Main Indications

Stem cell mobilization

Stem cell mobilization

Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia (AML)

Solid tumors

Solid tumors

Development

Motixafortide is currently being developed for several indications including mobilization of hematopoietic stem cells (HSCs) for autologous transplantation (Phase 3 completed), treatment of solid tumors (Phase 2), and other hematological malignancies (Phase 2).